Paragon 28 Inc
NYSE:FNA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (16.1), the stock would be worth $-5.2 (140% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -40.4 | $13.09 |
0%
|
| Industry Average | 16.1 | $-5.2 |
-140%
|
| Country Average | 13.3 | $-4.32 |
-133%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
P
|
Paragon 28 Inc
NYSE:FNA
|
1.1B USD | -40.4 | -20.1 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.7B USD | 54.7 | 58 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
163B USD | 17 | 26 | |
| US |
|
Stryker Corp
NYSE:SYK
|
122.9B USD | 24.4 | 37.9 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.1B USD | 14.4 | 22.8 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
86.7B USD | 19.1 | 24.3 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD | 30 | 43.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.8B EUR | 13.1 | 18.8 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.3B USD | 38.3 | 42.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.6B USD | 12.5 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.6B USD | 16.5 | 21.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8.8 |
| Median | 13.3 |
| 70th Percentile | 20.1 |
| Max | 3 188 432.5 |
Other Multiples
Paragon 28 Inc
Glance View
Paragon 28, Inc. engages in operation of an orthopedic foot and ankle company. The company is headquartered in Englewood, Colorado and currently employs 343 full-time employees. The company went IPO on 2021-10-15. The firm develops, distributes and markets medical devices in the foot and ankle segment of the orthopedic implant marketplace. The firm has developed a range of foot and ankle surgical systems and procedural techniques designed to address the primary conditions requiring treatment in the foot and ankle including fracture fixation, hallux valgus bunions, hammertoe, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, Charcot foot, and orthobiologics. The products used in foot and ankle procedures include screws, wires and pins, plates, nails, fixators, staples, joint implants, soft tissue implants, orthobiologics and other implantation instruments and disposables. The firm has developed approximately 6,600 implant, 1,200 instrument, and 900 disposable and other stock keeping units (SKU’s). The company has commercial footprint across United States and International.
